Regeneron Pharmaceuticals, Inc.
Financial Performance
Regeneron Revenue & Financials
Revenue
$14.3B (FY2025)
Market Cap
$75B
Net Income
$4.5B
Employees
15,410
What is Regeneron's revenue?
Regeneron had $14.3B in revenue for fiscal year 2025, up 1% from 2024. Net income was $4.5B.
- Latest revenue
- $14.3B (FY2025)
- Year-over-year
- +1%
- Growth rate (CAGR)
- 12.8% over 9 years
- Peak revenue
- $16.1B (FY2021)
- Years of data
- 10
- Employees
- 15,410
Financial Analysis
Regeneron's revenue rose from $4.86 billion in 2016 to $16.07 billion in 2021, inflated by COVID-19 antibody sales, then reset to $12.17 billion in 2022. It has since grown slowly: $13.12 billion in 2023, $14.20 billion in 2024 and $14.34 billion in 2025, as Dupixent gains offset lower original EYLEA sales. Growth picked up in 2026, with Q2 revenue up 17% to $4.3 billion, GAAP EPS of $12.23 and non-GAAP EPS of $14.29. Regeneron Pharmaceuticals, Inc. is a colossal American biotechnology company specializing in antibody therapeutics, sustaining a massive market valuation generally exceeding $100 billion.
Revenue Trend Analysis
YoY Change
+1%
9-Year CAGR
+12.8%
Peak Year
2021
Trend
Consistent Growth
Regeneron Pharmaceuticals, Inc. has 10 full fiscal year figures on this page, compounding at +12.8% annually over 9 years. The most recent year saw a 1% increase versus the prior year. Annual revenue peaked in fiscal year 2021 at $16.1B. Of 9 comparable year-over-year steps, 7 showed growth and 2 showed a decline.
Annual revenue history
Click any row to see year details.
Regeneron Pharmaceuticals, Inc. balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 10-K, linked on each row.
| Fiscal Year | Operating cash flow | Total assets | Total liabilities | Shareholders' equity | Source |
|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $5B | $40.6B | $9.3B | $31.3B | Form 10-K |
| FY2024ended Dec 31, 2024 | $4.4B | $37.8B | $8.4B | $29.4B | Form 10-K |
| FY2023ended Dec 31, 2023 | $4.6B | $33.1B | $7.1B | $26B | Form 10-K |
| FY2022ended Dec 31, 2022 | $5B | $29.2B | $6.6B | $22.7B | Form 10-K |
| FY2021ended Dec 31, 2021 | $7.1B | $25.4B | $6.7B | $18.8B | Form 10-K |
| FY2020ended Dec 31, 2020 | $2.6B | $17.2B | $6.1B | $11B | Form 10-K |
| FY2019ended Dec 31, 2019 | $2.4B | $14.8B | $3.7B | $11.1B | Form 10-K |
| FY2018ended Dec 31, 2018 | $2.2B | $11.7B | $3B | $8.8B | Form 10-K |
| FY2017ended Dec 31, 2017 | $1.3B | $8.8B | $2.6B | $6.1B | Form 10-K |
| FY2016ended Dec 31, 2016 | $1.5B | $7B | $2.5B | $4.4B | Form 10-K |
Related Companies
Compare Regeneron Pharmaceuticals, Inc. Revenue With Competitors
Keep researching Regeneron
Regeneron Revenue and Financial FAQ
What was Regeneron's revenue and net income for FY2025?
Regeneron reported FY2025 revenue of $14.34 billion and GAAP net income of $4.50 billion, versus $14.20 billion and $4.41 billion in 2024.
How did Regeneron perform in Q2 2026?
Q2 2026 revenue rose 17% to $4.3 billion. GAAP EPS was $12.23 and non-GAAP EPS $14.29, up 11%. Dupixent global sales reached $6.0 billion, Libtayo $489 million and U.S. EYLEA HD $596 million.
What is Regeneron's market capitalization?
About $75 billion in late September 2026, with shares near $751 and a P/E around 19.
How big was Regeneron's COVID-19 revenue boost?
Revenue jumped to $16.07 billion in 2021, largely from REGEN-COV antibody sales, then fell to $12.17 billion in 2022 as that demand disappeared.
How has EYLEA competition affected Regeneron's financials?
Original EYLEA sales have fallen as Roche's Vabysmo and aflibercept biosimilars gained share, keeping 2025 revenue growth near 1%. EYLEA HD growth and Dupixent profits have offset much of the decline.
Does Regeneron pay a dividend or buy back stock?
Regeneron runs share repurchase programs and began paying a quarterly cash dividend in 2025.
What is Regeneron’s annual revenue and earnings scale?
Regeneron generates between $13.0 billion and $14.5+ billion in annual gross revenues, producing over $4.0 billion in operating profit and consistent GAAP net income.
What is Dupixent’s global sales scale and Regeneron’s share?
Dupixent global net sales (recorded by Sanofi) exceed $13.0 billion to $15.0+ billion annually and are climbing past $16B+, delivering over $3.5B to $4.0+ billion in direct collaboration profits to Regeneron annually.
How much does Regeneron invest in Research & Development (R&D)?
Regeneron reinvests an industry-leading 30% to 35% of its annual revenues—typically $4.5 billion to $5.0+ billion per year—into scientific research, preclinical genetics, and clinical pipeline trials.
What is Regeneron’s balance sheet strength and cash position?
Regeneron possesses one of the strongest balance sheets in global biotechnology, holding over $16 billion in cash, cash equivalents, and marketable securities with negligible debt.
What is Regeneron’s shareholder capital return policy?
While Regeneron does not pay a regular dividend (reinvesting cash into R&D), it returns billions of dollars to shareholders through aggressive common stock buyback programs, repurchasing over $2 billion in shares annually.
How does biosimilar competition affect Eylea revenues?
While standard 2 mg Eylea faces patent expirations and biosimilar competition, Regeneron is successfully transitioning patients to high-dose Eylea HD (8 mg), which maintains strong patent exclusivity well into the late 2030s.
What are Regeneron’s gross profit margins on manufactured biologics?
Regeneron delivers high gross margins between 82% and 86% on direct net product sales, benefiting from large-scale automated bioreactors in New York and Ireland.
What is Regeneron’s pipeline commercial outlook?
Regeneron has more than 35 product candidates in clinical development across oncology, immunology, hematology, cardiovascular disease, rare genetic conditions, and infectious diseases.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Regeneron Revenue & Financials." CorpDigest, https://corpdigest.com/company/regeneron/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Regeneron reported $14.3B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/regeneron/financials" target="_blank" rel="noopener">CorpDigest — Regeneron financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore Regeneron
Core profile pages, founders and related research hubs for this company.